镰状细胞病患者COVID-19与静脉血栓栓塞风险
基于TriNetX多中心电子健康记录,识别2020年住院的镰状细胞病患者,比较合并COVID-19与未合并COVID-19两组在住院后6个月内静脉血栓栓塞发生率;调整基线特征后两组无显著差异(调整相对风险1.06,95%CI 0.79-1.41),提示合并COVID-19住院并未进一步增加镰状细胞病患者的静脉血栓栓塞风险。
要点
- 合并COVID-19住院的镰状细胞病患者6个月内静脉血栓栓塞发生率为12.46%。
- 未合并COVID-19住院的镰状细胞病患者6个月内静脉血栓栓塞发生率为8.58%。
- 调整基线特征后两组静脉血栓栓塞风险无显著差异(调整相对风险1.06,95%CI 0.79-1.41)。
核心结论
- 合并COVID-19住院并未进一步增加镰状细胞病患者的静脉血栓栓塞风险。
研究设计与样本
- 利用多中心研究网络TriNetX的电子健康记录数据,识别2020年住院的镰状细胞病患者,分为合并COVID-19组与未合并COVID-19组。
- 合并COVID-19住院组281例,未合并COVID-19住院组4873例。
- 采用带对数链接和稳健误差方差的调整泊松回归模型估计风险比,比较两组静脉血栓栓塞发生率。
主要发现
- 合并COVID-19住院组35例(12.46%)在指示住院后6个月内发生静脉血栓栓塞。
- 未合并COVID-19住院组418例(8.58%)在指示住院后6个月内发生静脉血栓栓塞。
- 调整基线特征差异后,两组6个月内静脉血栓栓塞发生率无显著差异(调整相对风险1.06,95%CI 0.79-1.41)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) is a life-threatening complication observed among patients with sickle cell disease (SCD) and also among those with severe COVID-19 infection. Although prior studies show that patients with SCD are at risk of severe COVID-19 illness, it remains unclear if COVID-19 infection further increases VTE risk for this population. We hypothesized that patients with SCD hospitalized for COVID-19 would have higher VTE rates than those hospitalized for other causes. Using electronic health record data from a multisite research network, TriNetX, we identified 2 groups of patients with SCD hospitalized during 2020: (1) with COVID-19 and (2) without COVID-19. We compared VTE rates using risk ratios estimated based on adjusted Poisson regression model with log link and robust error variances. Of the 281 SCD patients hospitalized with COVID-19 and 4873 SCD patients hospitalized without COVID-19 , 35 (12.46%) and 418 (8.58%) had incident VTE within 6 months of the index hospitalization respectively. After adjusting for differences in baseline characteristics, no significant differences in VTE rates within 6 months were found between the 2 groups (adjusted relative risk, 1.06 [95% confidence interval, 0.79-1.41]). These data suggest that hospitalization with COVID-19 does not further increase VTE risk in patients with SCD.
引用
- Singh A, Brandow AM, Wun T, et al. COVID-19 and venous thromboembolism risk in patients with sickle cell disease. Blood Adv. 2022. PMID: 35763429. doi:10.1182/bloodadvances.2022007219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。